Teladoc Health (NYSE:TDOC) Given New $18.00 Price Target at Royal Bank of Canada

Teladoc Health (NYSE:TDOC) had its target price cut by Royal Bank of Canada from $25.00 to $18.00 in a research report report published on Friday morning, Benzinga reports. They currently have an outperform rating on the health services provider’s stock.

Several other research firms also recently commented on TDOC. Cantor Fitzgerald started coverage on Teladoc Health in a report on Thursday, February 29th. They issued an overweight rating and a $22.00 target price on the stock. Stifel Nicolaus dropped their target price on Teladoc Health from $21.00 to $16.00 and set a hold rating on the stock in a report on Friday. Citigroup dropped their target price on Teladoc Health from $21.00 to $19.00 and set a neutral rating on the stock in a report on Wednesday, February 21st. SVB Leerink began coverage on Teladoc Health in a report on Monday, February 26th. They issued a market perform rating and a $17.00 target price on the stock. Finally, Barclays reduced their price objective on Teladoc Health from $25.00 to $20.00 and set an overweight rating for the company in a report on Friday. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Teladoc Health has an average rating of Hold and an average price target of $19.67.

Teladoc Health Price Performance

TDOC opened at $13.01 on Friday. The stock’s 50 day moving average price is $15.01 and its 200-day moving average price is $17.77. Teladoc Health has a 52-week low of $12.65 and a 52-week high of $30.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The firm had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. Teladoc Health’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.37) earnings per share. Analysts forecast that Teladoc Health will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other Teladoc Health news, EVP Andrew Turitz sold 6,190 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $89,878.80. Following the transaction, the executive vice president now directly owns 39,429 shares of the company’s stock, valued at $572,509.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Andrew Turitz sold 6,190 shares of Teladoc Health stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $89,878.80. Following the transaction, the executive vice president now directly owns 39,429 shares of the company’s stock, valued at approximately $572,509.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $19.18, for a total value of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares in the company, valued at $1,097,537.14. The disclosure for this sale can be found here. Over the last three months, insiders have sold 135,441 shares of company stock valued at $2,038,251. Insiders own 1.63% of the company’s stock.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its stake in Teladoc Health by 4.5% during the 4th quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock valued at $457,389,000 after purchasing an additional 912,692 shares during the period. Vanguard Group Inc. raised its stake in Teladoc Health by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares during the period. Dimensional Fund Advisors LP raised its stake in Teladoc Health by 25.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock valued at $82,636,000 after purchasing an additional 767,999 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Teladoc Health by 6.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,654,116 shares of the health services provider’s stock valued at $35,646,000 after purchasing an additional 104,531 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Teladoc Health by 9.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 658,435 shares of the health services provider’s stock valued at $12,240,000 after purchasing an additional 57,989 shares during the period. Institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.